J E Lancet

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. ncbi request reprint New agents: great expectations not realized
    Jeffrey E Lancet
    Oncologic Sciences, University of South Florida, Tampa, USA Department of Malignant Hematology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA Electronic address
    Best Pract Res Clin Haematol 26:269-74. 2013
  2. ncbi request reprint A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia
    J E Lancet
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Leukemia 25:1808-14. 2011
  3. pmc A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias
    Jeffrey E Lancet
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 17:1140-6. 2011
  4. doi request reprint Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia
    J E Lancet
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Leukemia 24:699-705. 2010
  5. pmc Novel postremission strategies in adults with acute myeloid leukemia
    Jeffrey E Lancet
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Curr Opin Hematol 16:105-11. 2009
  6. ncbi request reprint Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant
    Jeffrey E Lancet
    Department of Hematologic Malignancies, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Natl Compr Canc Netw 6:1017-25. 2008
  7. doi request reprint Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Curr Hematol Malig Rep 5:9-14. 2010
  8. doi request reprint Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome
    Celeste Bello
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer 117:1463-9. 2011
  9. pmc A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
    Jeffrey E Lancet
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Blood 109:1387-94. 2007
  10. doi request reprint A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia
    Jeffrey E Lancet
    Hematologic Malignancies Program, H Lee Moffitt Cancer Center, Tampa, FL, USA
    Leuk Res 33:1055-61. 2009

Detail Information

Publications11

  1. ncbi request reprint New agents: great expectations not realized
    Jeffrey E Lancet
    Oncologic Sciences, University of South Florida, Tampa, USA Department of Malignant Hematology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA Electronic address
    Best Pract Res Clin Haematol 26:269-74. 2013
    ..This review touches upon the potential reasons for these failures and explores the newer therapeutic approaches being pursued in AML...
  2. ncbi request reprint A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia
    J E Lancet
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Leukemia 25:1808-14. 2011
    ..Vosaroxin-induced DNA damage was detected as increased intracellular γH2AX. Vosaroxin had an acceptable safety profile, linear PK and encouraging clinical activity in relapsed/refractory leukemia...
  3. pmc A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias
    Jeffrey E Lancet
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 17:1140-6. 2011
    ..To determine the safety, target inhibition, and signals of clinical activity of tipifarnib in combination with bortezomib in patients with advanced acute leukemias...
  4. doi request reprint Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia
    J E Lancet
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Leukemia 24:699-705. 2010
    ..The twice-weekly administered alvespimycin was well tolerated in patients with advanced AML, showing linear pharmacokinetics, target inhibition and signs of clinical activity. We determined a recommended phase 2 dose of 24 mg/m(2)...
  5. pmc Novel postremission strategies in adults with acute myeloid leukemia
    Jeffrey E Lancet
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Curr Opin Hematol 16:105-11. 2009
    ....
  6. ncbi request reprint Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant
    Jeffrey E Lancet
    Department of Hematologic Malignancies, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Natl Compr Canc Netw 6:1017-25. 2008
    ..Future trials combining the novel therapies described in this article and novel transplant technologies should allow more elderly patients with AML or myelodysplastic syndromes to experience long and productive lives...
  7. doi request reprint Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Curr Hematol Malig Rep 5:9-14. 2010
    ..This article reviews the clinical experience with lenalidomide, highlighting recent understanding of the dual karyotype-dependent mechanisms of action...
  8. doi request reprint Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome
    Celeste Bello
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer 117:1463-9. 2011
    ..The authors evaluated predictive factors in patients with secondary AML treated with anthracycline-based induction therapy...
  9. pmc A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
    Jeffrey E Lancet
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Blood 109:1387-94. 2007
    ..Tipifarnib is active and well tolerated in older adults with poor-risk AML and may impart a survival advantage in those patients who experience a clinical response...
  10. doi request reprint A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia
    Jeffrey E Lancet
    Hematologic Malignancies Program, H Lee Moffitt Cancer Center, Tampa, FL, USA
    Leuk Res 33:1055-61. 2009
    ..gt; 90% P-gp inhibition was achieved within 2h at a plasma threshold of 132 ng/ml zosuquidar. The recommended phase II dose of zosuquidar is 700 mg/day...
  11. ncbi request reprint Farnesyl transferase inhibitors in myeloid disorders
    Jeffrey E Lancet
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
    Oncology (Williston Park) 19:1043-9; discussion 1049-50, 1053-4. 2005
    ....